Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
First Claim
Patent Images
1. The use of 40-O-(2-hydroxyethyl)-rapamycin in the manufacture of a medicament for co-administration in synergistically effective amounts with cyclosporin A.
0 Assignments
0 Petitions
Accused Products
Abstract
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
4 Citations
12 Claims
- 1. The use of 40-O-(2-hydroxyethyl)-rapamycin in the manufacture of a medicament for co-administration in synergistically effective amounts with cyclosporin A.
-
5. A kit of parts comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin in separate unit dosage forms, wherein said unit dosage forms are suitable for administration of the two compounds in synergistically effective amounts, together with instructions for use.
- 6. Cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin as a combined pharmaceutical preparation for simultaneous, separate or sequential use in synergistically effective amounts.
- 8. A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin in a synergistically effective ratio in combination or association with a pharmaceutically acceptable diluent or carrier.
Specification